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Accurately measuring the quality of cardiovascular care and
attempting to determine the sources of quality deficits are
difficult challenges, particularly in the outpatient setting.
Clinical trials have documented the benefits of warfarin in
atrial fibrillation, angiotensin-converting enzyme (ACE)
inhibitors in systolic heart failure, and aspirin and beta-
adrenergic blocking agents in myocardial infarction, and
these treatments have been adopted into clinical guidelines
(1–4). Despite the strong clinical evidence supporting the
uses of these treatments, numerous reports have shown that
their use is lower than ideal, although increasing with time
(5–12). Prior studies have suggested that utilization of these
drugs remains particularly low among patients cared for by
noncardiovascular specialists (13–17). These potential gaps
in quality have caused the Centers for Medicare and
Medicaid Services (formerly the Health Care Financing
Administration) to include these clinical conditions in the
group of conditions targeted for quality improvement.
Additionally, some third-party payers (i.e., Blue Cross Blue
Shield) have selected these clinical practice domains to
measure performance in an effort to provide incentive to
optimize care. However, in the absence of prospective case
review, determining the ideal rate of use of these medica-
tions in the outpatient clinical setting can be hampered by
incomplete access to clinical information needed to deter-
mine if particular patients are truly candidates for the
therapy.
See pages 56 and 62
In this issue of the Journal, Stafford et al. (18) describe
trends of prescribing patterns in the U.S. from 1990 to 2001
for patients seen in the outpatient setting with diagnosis
codes of atrial fibrillation, heart failure, and coronary artery
disease. The authors analyzed two ongoing national surveys
of office-based physicians’ prescribing patterns in the use of
recommended therapies for key cardiac conditions, the
National Ambulatory Medical Care Surveys (NAMCS) and
the National Disease and Therapeutic Index (NDTI). Both
datasets demonstrate steady increases in the use of these
recommended medications over the 12-year time period.
Remarkable increases were observed, in particular, with
warfarin use in atrial fibrillation (increasing from 12% in
1990 to 58% in 2001), beta-blocker use in coronary artery
disease (increasing from 19% in 1990 to 39% in 2001), and
aspirin use in coronary artery disease (increasing from 15%
in 1990 to 37% in 2001). More modest increases were
observed for ACE inhibitor use in congestive heart failure,
as rates increased from 24% in 1990 to 39% in 2001. The
authors comment that, although steady increases have
occurred over the study period, the strength of data sup-
porting these therapies is sufficient that more rapid adoption
of their use would have been expected. The gradual increase
in usage indicates that practitioners are slowly heeding the
message. The authors offer several explanations for this slow
rate of diffusion including lack of awareness of some
physicians, overemphasis on relative contraindications, and
lack of sufficient time in the outpatient clinical encounter to
address preventative treatments.
Investigators have also attempted to identify opportuni-
ties for quality improvement by studying the variances in
core quality measures. In this issue of the Journal, Ansari et
al. (19) report on the care of patients with new-onset heart
failure in the outpatient setting of a large managed care
health system based on the level of cardiologist participa-
tion. In this study 198 patients whose care included a
cardiologist were compared with 205 patients who were
treated by a primary care physician. The patients treated by
a cardiologist were more likely to receive care consistent
with clinical guidelines. In the cardiology treated patients,
94% underwent an evaluation of left ventricular function,
whereas only 74% of the primary care treated patients had
this measurement. In patients with a documented low
ejection fraction (45%), cardiologists prescribed patients
ACE inhibitors to 91%, while primary care physicians
prescribed this in 71% (both significantly higher than the
rate of ACE inhibitor use reported by Stafford et al. [18]).
More remarkable was the difference in beta-blocker use
(cardiologists, 38%; primary care physicians, 21%). Quality
differences were also demonstrated with respect to beta-
blocker and lipid-lowering therapy for coronary artery
disease, and warfarin use in atrial fibrillation. Additionally,
patients treated by a cardiologist were much more likely to
be evaluated for the presence of ischemic heart disease, the
most common reversible cause of heart failure. Ansari et al.
(19) further described the predictors of hospitalization
and/or death in these patients. While cardiology participa-
tion in care was not a univariate predictor of hospitalization,
death, or the combination, with multivariable analysis, it
was found to be an independent predictor of death and/or
cardiovascular hospitalization (hazard ratio, 0.62, 0.4 to 0.9;
p  0.02). Not surprisingly, a low left ventricular ejection
fraction was also a strong predictor.
Efforts to measure quality of cardiovascular care using
retrospective surveys may systematically underestimate ad-
herence to guideline recommendations. In the case of the
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NAMCS dataset, physicians were constrained to reporting
only five medications in 1990 to 1996, and six in 1997 to
1999. Many patients may take in excess of five or six
medications, particularly those with heart failure, and the
medications of interest may be omitted from the data form.
Additionally, contraindications to medications are not fully
attributed in either survey. In NAMCS, mechanisms were
instituted to exclude patients with additional diagnoses that
represent contraindications for medications under consider-
ation. For example, warfarin use for atrial fibrillation was
not required for patients with peptic ulcer disease, gastritis,
duodenitis, alcoholism, gait abnormalities, ataxia, Alzhei-
mer’s or other dementia, cerebral hemorrhage, seizure dis-
order, benign or malignant central nervous system tumors,
and renal insufficiency. Determination of the presence or
absence of these comorbidities was dependent on accurate
completion of encounter forms detailing clinical interac-
tions. It is likely that many existing contraindications are
missed using this strategy. In the NDTI, contraindications
to specific medications were not considered and, as a result,
many patients with clear contraindications to medications
remain in the denominator. Specific factors for each clinical
condition must also be considered.
Let us focus more precisely on each condition, starting
with stroke. While the annual stroke risk for patients with
atrial fibrillation not receiving anticoagulation is approxi-
mately 3% to 5% (20,21), estimating the risk of stroke is a
crucial factor in the decision to provide anticoagulation
therapy to individual patients with atrial fibrillation. The
American College of Cardiology/American Heart Associa-
tion/European Society of Cardiology atrial fibrillation prac-
tice guideline recommends aspirin in lieu of warfarin for all
patients75 years of age with lone atrial fibrillation and for
patients 60 years of age with heart disease but no specific
risk factors for stroke. It is believed that patients with annual
stroke risk 2% on aspirin do not benefit substantially from
oral anticoagulation with warfarin. Opinion is particularly
divided about anticoagulation for those at intermediate risk
for stroke (3% to 5% per year). Some advocate routinely
providing anticoagulation to patients with stroke risk in this
range, whereas others favor selective anticoagulation of
those at intermediate risk, with weight given to individual
bleeding risks and patient preferences (3).
Patients with a limited history of atrial fibrillation do not
necessarily require life-long oral anticoagulation. For exam-
ple, oral anticoagulation is recommended for patients with
postoperative atrial fibrillation due to the relatively high risk
of stroke in this setting. However, after the postoperative
healing is complete and the increased sympathetic tone of
the postoperative state has resolved, the risk of recurrent
atrial fibrillation is reduced, and warfarin treatment may be
discontinued. Similarly, patients with atrial-fibrillation-
associated thyrotoxicosis should be treated with oral anti-
coagulation, but once an euthyroid state is restored and
atrial fibrillation has been absent for six months, the
physician may choose to stop the warfarin treatment.
Physicians are well aware that anticoagulation increases the
frequency and severity of major extracranial and intracranial
hemorrhage. The major atrial fibrillation trials excluded
patients considered at high risk of bleeding. It is unclear
whether the relatively low rates of major hemorrhage in the
trials also apply to patients with atrial fibrillation in general
clinical practice, who are often older than 75 years and may
be more likely to harbor comorbidities that increase bleed-
ing risk.
To assess if warfarin is underused in the treatment of
patients with atrial fibrillation, Weisbold et al. (20) con-
ducted a cross-sectional study of 1,289 patients with atrial
fibrillation at a tertiary care Veteran’s Administration hos-
pital. While 65% (844) of the patients had filled at least one
warfarin prescription, of the remaining 445, 19 had died, 5
had inadequate medical records, 54 had received warfarin
elsewhere, 160 had no documentation of atrial fibrillation,
53 had only a remote history of atrial fibrillation, 49 had
only transient atrial fibrillation, 72 had documented contra-
indications to warfarin, and 17 refused warfarin therapy. Of
the 1,289 study patients with atrial fibrillation, only 16
(1.2%) were not receiving warfarin therapy and had no
identifiable justification, perhaps suggesting a very limited
provider knowledge deficit or, alternatively, imperfect doc-
umentation.
Let us consider key treatments for coronary heart disease
in the report by Stafford et al. (18). For both aspirin and
beta-blockers in coronary artery disease, there were substan-
tial increases in use noted between 1990 and 2001, but levels
remained below the 40% point in this analysis. While it is
possible that physicians may not be aware of the evidence
supporting the use of these medications, systematic errors
likely played a role in the low rates of usage reported.
Because aspirin does not require a prescription, it may be
more likely to be omitted from the medications listed on the
survey data forms. Additionally, contraindications to aspirin
use (allergy, gastritis, peptic ulcer disease, cerebral hemor-
rhage, iron deficiency anemia) may not be fully accounted
for in these series. Although the use of beta-blockers in the
setting of myocardial infarction and acute coronary syn-
dromes is well established, the level of evidence supporting
use of beta-blockers in chronic coronary artery disease is less
solid (1). Furthermore, physicians may not treat patients
with beta-blockers because of preexisting bronchospasm,
bradycardia, hypotension, or peripheral vascular disease.
Patients may also be reluctant to accept beta-blocker treat-
ment in the setting of mood disorders or sexual dysfunction.
Other studies of the treatment of patients with coronary
disease have shown far higher rates of use of aspirin and
beta-blockers than those reported by Stafford et al. (18).
Jollis et al. (16) reported that a series of Medicare patients
with myocardial infarction treated in 1992 were treated with
aspirin at rates of 74% (family practitioners), 79% (general
internists), and 85% (cardiologists). The use of beta-
blockers by family practitioners, general internists, and
cardiologists in this analysis was reported lower, at 35%,
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40%, and 52%, respectively. Although Stafford et al. (18)
and others have documented steady increases in aspirin and
beta-blocker use for coronary artery disease, it is likely that
the substantial differences between the percentages Jollis
reported from 1992 and those in this issue of the Journal are
due to fundamental differences in study design.
The use of ACE inhibitors in heart failure is recom-
mended for all patients with left ventricular ejection fraction
40% (4). While ACE inhibitors may be useful in the
treatment of patients with heart failure and preserved left
ventricular systolic function, particularly in the presence of
hypertension, coronary artery disease, and diabetes, no large
clinical trial evidence exists to base a broad-based recom-
mendation for the use of ACE inhibitors in all patients with
heart failure. The heart failure data from the NAMCS and
NDTI surveys do not distinguish between systolic heart
failure and heart failure with preserved systolic function.
Most large studies suggest that approximately one-third of
patients with heart failure in the absence of significant
valvular disease have preserved left ventricular systolic dys-
function and are believed to have an abnormality of ven-
tricular relaxation. We suspect that inclusion of these
patients in the denominator of treated heart failure patients
leads to a significant underestimation of the use of ACE
inhibitors among appropriate patients.
Analysis of the NAMCS dataset excluded heart failure
patients with hyperkalemia. Neither the NAMCS nor the
NDTI survey accounted for prior intolerance to ACE
inhibitors due to angioedema, cough, or renal dysfunction.
Also, patients with symptomatic hypotension, bilateral renal
artery stenosis, and severe aortic stenosis were not excluded
from these analyses. Prior investigators, taking these various
factors into account, have shown that ACE inhibitor use in
systolic heart failure is in excess of 80%, even in the elderly
population (22). Thus, the real room for improvement is
probably much less than Stafford et al. (18) suggest. Al-
though we would like to believe we could reach 100%
compliance with ACE inhibitor use for systolic heart failure,
imperfections of the paper medical record and abstraction
method make this level of adherence unlikely. For these and
other reasons, some experts have suggested that it may not
be possible to increase the measured rate of ACE inhibitor
use 85% (23).
Whether the differences between the care of patients
treated by primary care providers or cardiovascular special-
ists are “real” or due to systematic differences in study design
is unclear. While cardiologists may be quick to accept the
results of Ansari et al. (19), one must first recognize the
important differences in the two study groups. Patients
treated by a cardiologist were younger, were more likely to
be male, and were more likely to have coronary artery
disease. Patients of cardiologists had lower ejection fractions
and were more likely to have atrial fibrillation, but were less
likely to have diabetes or chronic obstructive pulmonary
disease. Patients of cardiologists appear to have had more
overt heart failure, thus leading to referral to a specialist and
making the diagnosis and treatment plan clearer.
Also, differences in the populations that were not assessed
by the study may have existed and might explain the lower
rate of adverse clinical outcomes seen with the cardiologist
treated patients. Certainly, the relatively greater age of the
primary care treated patients would help explain some of
this difference. Medical comorbidities seen more frequently
in the primary care treated patients suggest that these
patients may have been more fragile and may have been
perceived to be less likely to benefit from specialty care.
Known predictors of prognosis such as serum sodium, heart
rate, blood pressure, QRS interval, and peak oxygen con-
sumption were not addressed in this study (24).
Delivering the highest quality of care for patients with
cardiovascular disease is necessary to achieve the best pos-
sible clinical outcomes. Determination of the quality of care
requires measurable indicators that provide a meaningful
yardstick to gage the merit of clinical care. Practitioners and
investigators must realize that performance measures can be
accurately measured only if there is adequate disclosure of
attributes of the patient population so that indications and
contraindications are easily assessed. Unfortunately, clinical
trials often exclude higher risk patients, and, thus, the
relative merits and risks of therapies may be unknown.
Furthermore, the degree to which medical records allow
true confidence regarding indications and contraindications
is highly variable. We must move forward in the science of
measuring and improving clinical care. It is believed that
better standardization of care encounters, use of electronic
records, and incorporation of guideline-based reminders will
represent the next steps in the development of systems that
help us provide evidence-based care and, at the same time,
identify opportunities where we can improve.
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